Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α
Overview
Authors
Affiliations
Little is known about the association between myeloid-derived suppressor cell (MDSC) subsets and various chemokines in patients with renal cell carcinoma (RCC) or the factors that draw MDSC into tumor parenchyma. We analyzed polymorphonuclear MDSC (PMN-MDSC), monocytic MDSC (M-MDSC), and immature MDSC (I-MDSC) from the parenchyma and peripheral blood of 48 patients with RCC, isolated at nephrectomy. We analyzed levels of IL1β, IL8, CXCL5, Mip-1α, MCP-1, and Rantes. Furthermore, we performed experiments in a Renca murine model to assess therapeutic synergy between CXCR2 and anti-PD1 and to elucidate the impact of IL1β blockade on MDSC. Parenchymal PMN-MDSC have a positive correlation with IL1β, IL8, CXCL5, and Mip-1α, and I-MDSC correlate with IL8 and CXCL5. Furthermore, peripheral PMN-MDSC correlate with tumor grade. Given that PMN-MDSC express CXCR2 and parenchymal PMN-MDSC correlated with IL8 and CXCL5, we assessed the response of CXCR2 blockade with or without anti-PD1. Combination therapy reduced tumor weight and enhanced CD4 and CD8 T-cell infiltration. In addition, anti-IL1β decreased PMN-MDSC and M-MDSC in the periphery, PMN-MDSC in the tumor, and peripheral CXCL5 and KC. Anti-IL1β also delayed tumor growth. Parenchymal PMN-MDSC have a positive correlation with IL1β, IL8, CXCL5, and Mip-1α, suggesting they may attract PMN-MDSC into the tumor. Peripheral PMN-MDSC correlate with tumor grade, suggesting prognostic significance. Anti-CXCR2 and anti-PD1 synergized to reduce tumor weight and enhanced CD4 and CD8 T-cell infiltration in a Renca murine model, suggesting that CXCR2 PMN-MDSC are important in reducing activity of anti-PD1 antibody. Finally, anti-IL1β decreases MDSC and delayed tumor growth, suggesting a potential target for MDSC inhibition. .
Liu J, Pan R Front Pharmacol. 2024; 15:1495970.
PMID: 39555095 PMC: 11565697. DOI: 10.3389/fphar.2024.1495970.
Stransky L, Gao W, Schmidt L, Bi K, Ricketts C, Ramesh V Proc Natl Acad Sci U S A. 2024; 121(41):e2408549121.
PMID: 39365820 PMC: 11474080. DOI: 10.1073/pnas.2408549121.
Li Y, Wu Z, Ni C, Li Y, Wang P Discov Oncol. 2024; 15(1):512.
PMID: 39347882 PMC: 11442913. DOI: 10.1007/s12672-024-01405-2.
Pre-metastatic niche: formation, characteristics and therapeutic implication.
Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q Signal Transduct Target Ther. 2024; 9(1):236.
PMID: 39317708 PMC: 11422510. DOI: 10.1038/s41392-024-01937-7.
Wang Z, Zhou L, Wu X Oncol Res. 2024; 32(9):1479-1516.
PMID: 39220130 PMC: 11361912. DOI: 10.32604/or.2024.048564.